Vertex (VRTX) EVP Amit Sachdev exercises options and sells 58,613 shares

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Amit Sachdev reported option exercises and share sales. On February 19, 2026, he exercised stock options covering 23,479 shares at a price of $155.57 per share and 25,026 shares at $187.53 per share, converting them into common stock.

On the same date, he sold a total of 58,613 shares of common stock in multiple open-market transactions at prices ranging from approximately $463.91 to $471.43, under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025. Following these transactions, he held 58,934 shares directly, plus 882 shares in a 401(k) and 9,301 shares held in a trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sachdev Amit

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Patient & Ext Af Off

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		M		23,479	A	$155.57	92,521	D
Common Stock	02/19/2026		M		25,026	A	$187.53	117,547	D
Common Stock	02/19/2026		S(1)		920	D	$463.91(2)(3)	116,627	D
Common Stock	02/19/2026		S(1)		2,730	D	$465.05(3)(4)	113,897	D
Common Stock	02/19/2026		S(1)		1,848	D	$465.8(3)(5)	112,049	D
Common Stock	02/19/2026		S(1)		10,263	D	$467.75(3)(6)	101,786	D
Common Stock	02/19/2026		S(1)		19,662	D	$468.57(3)(7)	82,124	D
Common Stock	02/19/2026		S(1)		7,241	D	$469.61(3)(8)	74,883	D
Common Stock	02/19/2026		S(1)		11,712	D	$470.54(3)(9)	63,171	D
Common Stock	02/19/2026		S(1)		4,237	D	$471.43(3)(10)	58,934	D
Common Stock								882	I	401(k)
Common Stock								9,301	I	Held in Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$155.57	02/19/2026		M			23,479	(11)	02/05/2028	Common Stock	23,479	$0	0	D
Stock Option (Right to Buy)	$187.53	02/19/2026		M			25,026	(11)	02/05/2029	Common Stock	25,026	$0	0	D

Explanation of Responses:

1. Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025.

2. Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28).

3. Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46).

5. Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49).

6. Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05).

7. Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09).

8. Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05).

9. Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08).

10. Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03).

11. Fully vested.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vertex (VRTX) executive Amit Sachdev report in this Form 4?

Amit Sachdev reported exercising stock options and selling common shares of Vertex. He converted option awards into common stock, then sold 58,613 shares in multiple open-market trades, while retaining a significant direct and indirect ownership position after the transactions.

How many Vertex (VRTX) shares did Amit Sachdev sell and at what prices?

He sold 58,613 shares of Vertex common stock in several open-market transactions. Reported weighted average prices ranged from about $463.91 to $471.43 per share, with detailed price ranges for each sale line disclosed in the accompanying footnotes.

What stock options did Amit Sachdev exercise in the Vertex (VRTX) filing?

He exercised stock options covering 23,479 shares at an exercise price of $155.57 and 25,026 shares at $187.53 per share. These option exercises were fully vested and resulted in the acquisition of an equivalent number of Vertex common shares.

How many Vertex (VRTX) shares does Amit Sachdev own after these transactions?

After the reported transactions, he directly owns 58,934 shares of Vertex common stock. In addition, he holds 882 shares indirectly through a 401(k) plan and 9,301 shares indirectly through a trust, as reflected in the holding entries.

Was Amit Sachdev’s sale of Vertex (VRTX) shares under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a company-approved trading plan entered into on November 18, 2025, pursuant to Rule 10b5-1, which allows pre-scheduled trades according to predetermined instructions.

What role does Amit Sachdev hold at Vertex (VRTX)?

In this filing, Amit Sachdev is identified as an officer of Vertex, serving as Executive Vice President, Chief Patient & External Affairs Officer, which is disclosed in the reporting person information section of the Form 4 data.